Vaderis Raises $152 Million to Fund Phase 3 Trial of AKT Inhibitor Engasertib in Hereditary Haemorrhagic Telangiectasia
核心洞察
Vaderis Therapeutics (搜索) secured $152 million in Series B financing led by Goldman Sachs Alternatives (搜索) and TCGX (搜索) to fund its HEROIC phase 3 trial of engasertib (搜索).
Engasertib (搜索), an AKT (搜索) inhibitor, targets hereditary haemorrhagic telangiectasia (搜索) (HHT), a rare vascular disorder with no FDA-approved therapies.
In a phase 2 trial, engasertib (搜索) reduced both the frequency and duration of nosebleeds in patients with HHT.
Switzerland-based Vaderis Therapeutics (搜索) has raised $152 million in second-round financing to advance its AKT (搜索) inhibitor engasertib (搜索) into a pivotal phase 3 trial for hereditary haemorrhagic telangiectasia (搜索) (HHT), a rare vascular disorder that currently has no FDA-approved therapies. The financing was led by Goldman Sachs Alternatives (搜索) and TCGX (搜索).
The proceeds will fund the company's just-started HEROIC phase 3 trial of engasertib (搜索) as a treatment for HHT. People living with HHT have blood vessels that have not developed properly, a condition known as arteriovenous malformations (AVMs), and suffer symptoms including regular and persistent nosebleeds, red spots on the body, and anaemia.
In a phase 2 trial, engasertib (搜索) reduced both the frequency and duration of nosebleeds, providing the clinical rationale for advancing the candidate into late-stage development. The drug is an AKT (搜索) inhibitor, representing a novel mechanistic approach to a disease with significant unmet medical need.
The financing round drew participation from a broad syndicate of investors, including Omega Funds, EQT Life Sciences, Perceptive Life Sciences, Medicxi (CalPERS), Kalehua Capital Partners, and existing investors Medicxi and Droia.
The investment underscores growing venture capital interest in rare disease therapeutics, particularly where no approved treatment options exist. With the HEROIC phase 3 trial now underway, Vaderis aims to establish engasertib (搜索) as a potential first approved therapy for HHT.